Serial blood-based analysis of AR-V7 in men with advanced prostate cancer

Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer

(2015) Robert J. van Soest et al.   EUROPEAN UROLOGY

Sequencing of agents in castration-resistant prostate cancer

(2015) David Lorente et al.   LANCET ONCOLOGY

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer

(2014) Rosa Nadal et al.   PROSTATE

Androgen Receptor Splice Variants in the Era of Enzalutamide and Abiraterone

(2014) Mary Nakazawa et al.   Hormones & Cancer

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)

(2013) Y. Loriot et al.   ANNALS OF ONCOLOGY

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone

(2013) D. Bianchini et al.   EUROPEAN JOURNAL OF CANCER

Targeting the Adrenal Gland in Castration-Resistant Prostate Cancer: A Case for Orteronel, a Selective CYP-17 17,20-Lyase Inhibitor

(2013) Hui Zhu et al.   Current Oncology Reports

A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509

(2013) J. D. Joseph et al.   Cancer Discovery

Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines

(2012) Y. Li et al.   CANCER RESEARCH

Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants

(2011) Elahe A. Mostaghel et al.   CLINICAL CANCER RESEARCH

Alternatively spliced androgen receptor variants

(2011) Scott M Dehm et al.   ENDOCRINE-RELATED CANCER

Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer

(2011) K.-H. Chang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities

(2011) Rong Hu et al.   PROSTATE

A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth

(2009) Z. Guo et al.   CANCER RESEARCH

Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate Cancer

(2008) J. A. Locke et al.   CANCER RESEARCH

Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer

(2008) R. Hu et al.   CANCER RESEARCH